The IMPRES prediction is based on the 15 pairwise relations between the expression of immune checkpoint genes16, which were selected using the training data of regressing and progressing neuroblastoma but not melanoma patient samples, treated with anti-PD1. This evidence concerns the gene PDCD1 and melanoma.